8-K: Arcutis Soars on ZORYVE Sales, Raises 2026 Guidance

Arcutis Biotherapeutics reported strong Q4 and full-year 2025 financial results, driven by ZORYVE sales growth, positive clinical data, and increased 2026 revenue guidance.

Summary

• Q4 2025 net product revenue for ZORYVE was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025.
• Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior year.
• Reported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis.
• A Supplemental New Drug Application (sNDA) submission for ZORYVE cream 0.05% for infants is expected in Q2 2026.
• Announced expansion of its dermatology sales force and initiated a targeted commercialization effort for primary care and pediatric health care providers.
• Produced positive operating cash flow of $26.2 million in Q4 2025 and anticipates maintaining positive operating cash flow on a quarterly basis going forward.
• Raised 2026 full year net product sales guidance to $480 million $495 million, up from the previous range of $455 million $470 million.
• Net income was $17.4 million, or $0.14 per basic share, for Q4 2025, compared to a net loss of $10.8 million, or $0.09 per basic share, for Q4 2024.
• Net loss for the full year 2025 was $16.1 million, or $0.13 per basic share, a significant reduction from a net loss of $140.0 million, or $1.16 per basic share, for 2024.
• Secured Medicare access for ZORYVE beginning in January 2026, with approximately one in three Medicare patients now having non-preferred access.
• Launched ZORYVE cream 0.05% for the treatment of atopic dermatitis in children ages 2 to 5 years old following FDA approval in early October 2025.
• Mutually agreed to terminate the promotion agreement with Kowa in January 2026, with the company planning to assume responsibility for sales and promotion of ZORYVE in pediatric and primary care settings.
• An sNDA for ZORYVE cream 0.3% for the treatment of plaque psoriasis down to 2 years of age was accepted, with a PDUFA target action date set for June 29, 2026.
• Obtained one new U.S. patent in Q4 2025 related to topical roflumilast foam compositions, extending exclusivity in the United States for the foam formulation from 2041 to 2042.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, driven by strong ZORYVE sales growth, a significant reduction in net loss, achievement of positive operating cash flow, and an upward revision of future revenue guidance, indicating robust commercial execution and pipeline progress.

Positives

• Significant growth in ZORYVE net product revenue: 84% year-over-year in Q4 2025 and 123% for full year 2025.
• Achieved positive operating cash flow of $26.2 million in Q4 2025 and expects to maintain it quarterly.
• Raised 2026 full-year net product sales guidance to $480 million $495 million, indicating strong future expectations.
• Transitioned from a net loss of $10.8 million in Q4 2024 to a net income of $17.4 million in Q4 2025.
• Reduced full-year net loss from $140.0 million in 2024 to $16.1 million in 2025.
• Reported positive topline data for ZORYVE cream 0.05% in infants (3-24 months) with atopic dermatitis, expanding potential market.
• FDA approval and launch of ZORYVE cream 0.05% for children ages 2 to 5 years old in early October 2025.
• Secured Medicare access for ZORYVE starting January 2026, broadening patient reach.
• Expansion of dermatology sales force and initiation of targeted commercialization efforts for primary care and pediatric healthcare providers.
• New U.S. patent extends exclusivity for topical roflumilast foam compositions to 2042.
• sNDA accepted for ZORYVE cream 0.3% for plaque psoriasis down to 2 years of age with a PDUFA date of June 29, 2026.

Negatives

• Other revenue decreased significantly from $30.0 million in 2024 to $4.0 million in 2025, primarily due to a non-recurring $25.0 million upfront payment from the Sato Japan License Agreement in 2024.
• Cash and cash equivalents decreased from $71.335 million as of December 31, 2024, to $42.907 million as of December 31, 2025.
• Net cash used in operating activities for the full year 2025 was $5.6 million, despite a positive Q4, indicating continued cash burn over the full year.

Risks

• Risks inherent in the clinical development process and regulatory approval process.
• Uncertainty regarding the timing of regulatory filings.
• Uncertainty regarding the timing, expenses, and success of commercialization efforts.
• Uncertainty of future commercial sales and related items that can impact net sales.
• Ability to defend intellectual property.

Future Outlook

The company raised its full-year 2026 net product revenue guidance to $480 million $495 million, an increase from the previous range of $455 million $470 million. It anticipates maintaining positive operating cash flow on a quarterly basis going forward. The company plans an sNDA submission for ZORYVE cream 0.05% for infants in Q2 2026 and expects program advancement decisions for ZORYVE foam in vitiligo and hidradenitis suppurativa in Q4 2026 and Q1 2027, respectively. A Phase 1 study for ARQ-234 is expected to enroll its first patient in Q1 2026.

Management Comments

• "In 2025, Arcutis continued its strong performance trend, with more than 90% year-over-year growth in net product revenue, reflecting strong demand for ZORYVE, successful execution across multiple product launches that leveraged ZORYVEs differentiated profile, and early penetration into the large topical steroid market."
• "We enter the next phase of our growth with a solid cash position and the resources to invest both in ZORYVEs continued growth and expansion, and to build and advance our pipeline through our world-class development organization."

Industry Context

StockSavvy.ai notes that Arcutis's strong performance in immuno-dermatology, particularly with ZORYVE, positions it well in a competitive market for inflammatory skin diseases. The expansion into pediatric indications and primary care settings, coupled with securing Medicare access, suggests a strategic effort to broaden market penetration and capture a larger share of the topical steroid market, which is a significant growth area. The development of ARQ-234 also indicates a commitment to pipeline diversification beyond PDE4 inhibitors.

Comparison to Industry Standards

• The 123% year-over-year growth in ZORYVE net product revenue for 2025 is exceptionally strong, significantly outpacing typical growth rates for established pharmaceutical products and indicating successful market penetration for a relatively new product.
• Achieving positive operating cash flow in Q4 2025 and projecting its maintenance is a critical milestone for a commercial-stage biopharmaceutical company, often distinguishing successful commercialization from those still heavily reliant on external funding.
• The expansion of ZORYVE's indications to younger pediatric populations (2-5 years and 3-24 months) aligns with a broader industry trend of addressing unmet needs in specific patient demographics, similar to how companies like Sanofi/Regeneron with Dupixent have expanded into younger age groups for atopic dermatitis.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved profitability, positive cash flow, and raised guidance, potentially leading to increased share value.
• Patients: Increased access to ZORYVE through Medicare and expanded indications for younger age groups, addressing unmet needs in atopic dermatitis and psoriasis.
• Employees: Expansion of the dermatology sales force suggests job growth and increased commercial activity.
• Competitors: Increased competition in the immuno-dermatology market, particularly for topical treatments for psoriasis and atopic dermatitis.

Next Steps

• Submit sNDA for ZORYVE cream 0.05% for infants (3-24 months) in Q2 2026.
• PDUFA target action date for sNDA of ZORYVE cream 0.3% for plaque psoriasis down to 2 years of age is June 29, 2026.
• Enroll first patient in Phase 1 study of ARQ-234 in Q1 2026.
• Report decisions on program advancement for ZORYVE foam 0.3% in vitiligo in Q4 2026.
• Report decisions on program advancement for ZORYVE foam 0.3% in hidradenitis suppurativa in Q1 2027.
• Maintain positive operating cash flow on a quarterly basis.
• Continue commercialization efforts for ZORYVE, including expanded sales force and targeted primary care/pediatric efforts.

Key Dates

Recommendation

The company demonstrated exceptional financial performance with ZORYVE, achieving significant revenue growth, a substantial reduction in net loss, and a shift to positive operating cash flow. The upward revision of 2026 guidance, successful expansion into pediatric indications, and pipeline advancements signal strong commercial momentum and future growth potential. These factors collectively present a compelling investment case for a seasoned investor.

Keywords

Arcutis Biotherapeutics, ARQT, ZORYVE, roflumilast, plaque psoriasis, atopic dermatitis, seborrheic dermatitis, immuno-dermatology, financial results, Q4 2025, full year 2025, net product revenue, operating cash flow, sNDA, FDA, clinical trials, INTEGUMENT-INFANT, ARQ-234, dermatology, biopharmaceutical